Next Article in Journal
Anticarcinogenic and Antioxidant Action of an Edible Aquatic Flora Jussiaea repens L. Using In Vitro Bioassays and In Vivo Zebrafish Model
Next Article in Special Issue
Synthesis and Antiplasmodial Activity of Bisindolylcyclobutenediones
Previous Article in Journal
Biosynthesis and Anti-Mycotoxigenic Activity of Zingiber officinale Roscoe-Derived Metal Nanoparticles
Previous Article in Special Issue
Bimetallic Iron–Palladium Catalyst System as a Lewis-Acid for the Synthesis of Novel Pharmacophores Based Indole Scaffold as Anticancer Agents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 8
10.3390/molecules26082292
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design, Synthesis, and Antimicrobial Activity of Certain New Indole-1,2,4 Triazole Conjugates

by
Reem I. Al-Wabli
1,*,
Mona A. Alsulami
1,
Sarah I. Bukhari
2,
Nadine M. S. Moubayed
3,
Maha S. Al-Mutairi
1 and
Mohamed I. Attia
1,4,*
1
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
2
Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
3
Botany and Microbiology Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
4
Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (ID: 60014618), El Bohooth Street, Dokki, Giza 12622, Egypt
*
Authors to whom correspondence should be addressed.
Molecules 2021, 26(8), 2292; https://doi.org/10.3390/molecules26082292
Submission received: 17 March 2021 / Revised: 6 April 2021 / Accepted: 12 April 2021 / Published: 15 April 2021
(This article belongs to the Special Issue Indole Derivatives: Synthesis and Application II)
Browse Figure
Versions Notes

Abstract

:
The increasing prevalence of microbial infections and the emergence of resistance to the currently available antimicrobial drugs urged the development of potent new chemical entities with eminent pharmacokinetic and/or pharmacodynamic profiles. Thus, a series of new indole-triazole conjugates 6a-u was designed and synthesized to be assessed as new antimicrobial candidates using the diameter of the inhibition zone and minimum inhibitory concentration assays against certain microbial strains. Their in vitro antibacterial evaluation revealed good to moderate activity against most of the tested Gram-negative strains with diameter of the inhibition zone (DIZ) values in the range of 11–15 mm and minimum inhibition concentration (MIC) values around 250 µg/mL. Meanwhile, their in vitro antifungal evaluation demonstrated a potent activity against Candida tropicalis with MIC value as low as 2 µg/mL for most of the tested compounds. Moreover, compound 6f is the most potent congener with an MIC value of 2 µg/mL against Candida albicans.

1. Introduction

Bacterial infections are the major cause of some high mortality rate diseases such as typhus, tuberculosis, plague, diphtheria, cholera, dysentery, and pneumonia. On the other hand, fungi infect many people worldwide every year, yet their contribution to the global burden of diseases is largely unrecognized, and most of them cause relatively minor infections but kill at least as many people as tuberculosis or malaria [1]. This is due to an increasing population with reduced immune system or immunocompromised individuals having AIDS, cancer or those undergoing organ transplantation. Furthermore, microbial infections are becoming more resistant to antibiotics due to years of their overuse and/or misuse, which might lead to a potential global health disaster [2]. In addition, the current hospital-acquired infections are resistant to most of the clinically available antibiotics such as methicillin and vancomycin. Therefore, the use of these drugs was reserved to treat only the most intractable infections to retard the development of their resistance [3,4,5]. This makes the design and development of new antimicrobial candidates with novel chemical structures and/or with different modes of action rather than analogues of the existing ones are necessary for clinical needs.
Indole ring is one of the most potent pharmacodynamic nucleus and constitutes the backbone of the neurotransmitter serotonin and the natural hormone melatonin as well as the essential amino acid tryptophan. The recognition of tryptophan importance in animal and human nutrition served to bring about a renaissance in indole chemistry, and therefore, indole derivatives have been synthesized and/or isolated from nature in abundance. Mitomycin is an example of bioactive indole alkaloids and its analogues are gaining great attention because of their extensive use in cancer chemotherapy and for its antibacterial activity [6,7]. Consequently, compounds bearing an indole nucleus have a considerable importance in the development of diverse bioactive compounds by varying the substituents or substitution pattern of the indole ring. Such compounds have been reported for various biological activities including antimicrobial [8], antiviral [9], anticonvulsant [10], analgesic, anti-inflammatory anti-tubercular [11] and anticancer [12]. Thus, this wide spectrum of activities of indole-bearing compounds makes them suitable candidates for the development of novel antibacterial and antifungal treatments. On the other hand, there has been a considerable interest in the development of novel heterocyclic compounds with variable biological activities. Among them, triazoles are a special class of heterocyclic compounds with a broad spectrum of biological activities such as antibacterial [13,14], antifungal [15,16], anti-inflammatory [17], antitubercular [18], anticancer [19], antimalarial [20], antiviral [21], and analgesic [22]. Furthermore, fluconazole and itraconazole [23] are therapeutically significant antifungal azoles containing 1,2,4-triazole moiety.
Hybridization is an important modality in drug design and development based on a combination of biologically active moieties to produce a new hybrid compound with an improved biological activity when compared to the parent compounds. Additionally, this strategy can result in compounds presenting a modified selectivity profile, different and/or dual modes of action, and reduced undesired side effects [24]. A literature review revealed that 1,2,4 triazole-indole hybrid compounds were synthesized and demonstrated excellent antibacterial and antifungal activity [25]. In addition, it was found that a free N–H in the indole ring was essential and increased the antibacterial activity to an acceptable extent against K. pneumoniae, E. coli, and P. aeruginosa [26]. Moreover, the 1,2,4-triazole nucleus has received attention due to its low toxicity, wide safety, and good pharmacokinetic characteristics [27], and it was noticed that upon the introduction of the electron-rich sulfur atom into the triazole ring, the bioactivities of the target compounds greatly improve [28]. This may be attributed to the effect of the sulfur atom in increasing the lipophilicity and modulating of the electron density in the triazole ring, which increases the transmembrane diffusion and their interaction with macromolecular targets [29].
On the basis of the aforementioned premises, it was of our interest to design and synthesize certain indole-based 1,2,4-triazole-3-thiol molecular hybrids 6a-u with different N4 substituent on the triazole nucleus with increasing order of lipophilicity (cyclohexyl < phenyl < 4-Cl-phenyl) and to test their antibacterial and antifungal activities.

2. Results and Discussions

2.1. Chemistry

The target compounds 6a-u have been successfully synthesized according to Scheme 1. The synthesis was commenced by esterification of the commercially available indole-2-carboxylic acid (1) in ethanol in the presence of a catalytic amount of sulfuric acid. The ethyl ester derivative 2 was converted to the corresponding acid hydrazide 3 through reaction with hydrazine hydrate in ethanol. Subsequently, the appropriate isothiocyanate, namely cyclohexyl isothiocyanate, phenyl isothiocyanate, and 4-chlorophenyl isothiocyanate was allowed to react with compound 3 to yield the respective thiosemicarbazide derivatives 4a-c. Cyclodehydration reaction of the thiosemicarbazide derivatives 4a-c was carried out in aqueous 10% NaOH to give compounds 5a-c. Thereafter, the target compounds 6a-u were achieved through a nucleophilic substitution reaction in which the appropriate benzyl halide was subjected to nucleophilic attack by the thiol group of compounds 5a-c. It is noteworthy to mention that the use of polar protic solvents such as ethanol, in a strong alkaline medium such as sodium hydroxide, favors the formation of both S-alkyl derivatives as major products and N-alkyl derivatives as minor products. On the other hand, carrying out the reaction in a polar aprotic solvent such as acetone, in the presence of potassium carbonate favors the formation of S-alkyl derivatives as a sole product [30]. Thus, the triazole derivatives 5a-c were elaborated to their respective N-alkyl derivatives 6a-u as sole products through the reaction with the appropriate benzyl halide in dry acetone [31]. The 1H-NMR spectra of compounds 6a-u showed the cyclohexyl protons for compounds 6o-u in the range of δ = 1.05-4.40 ppm. Meanwhile, compounds 6g, 6n, and 6u showed singlets at δ = 2.28 ppm representing three protons of CH3 group. Singlets integrated for two protons were noticed in the range of δ = 4.36-4.70 ppm, which were assigned to be for the two protons of the benzylic CH2. The aromatic protons were observed in the region of δ = 6.94-8.19 ppm. Additionally, the SH signals disappeared, and the 13C-NMR spectra of the target compounds 6a-u exhibited signals in the range of δ = 34.7-37.3 ppm indicating carbons of the benzylic CH2. The cyclohexyl carbons for compounds 6o-u were observed in the range of δ = 24.9-56.8 ppm and the aromatic carbons appeared in the range of δ = 101.8-151.7 ppm.

2.2. Antimicrobial Evaluation

The in vitro antibacterial potential of the tested compounds 6a-u was estimated against five standard bacterial strains, namely the Gram-negative Escherichia coli, Pseudomonas aeruginosa, and Salmonella, and the Gram-positive Staphylococcus aureus and Bacillus subtilis. Meanwhile, the antifungal potential was estimated against three standard fungal strains, namely Candida albicans, Candida tropicalis, and Candida glabrata. The results are expressed as diameter of the inhibition zone (DIZ) and the minimum inhibition concentration (MIC). Ampicillin (antibacterial) and fluconazole (antifungal) were used as reference drugs, and the antimicrobial results are presented in Table 1 and Table 2.
Table 1 illustrates the antibacterial activity of the target compounds 6a-u in the DIZ and MIC assays against the tested bacterial strains. They showed varying degrees of activities against the tested microorganisms. Most of the investigated compounds 6a-u manifested good to moderate activity in the DIZ assay toward the tested Gram-negative bacterial strains with DIZ values in the range of 11-15 mm. Whereas, their MIC value was around 250 µg/mL which is lower than the MIC values of ampicillin against Escherichia coli (500 µg/mL), Pseudomonas aeruginosa (1000 µg/mL), and Salmonella (500 µg/mL). In addition, Gram-positive bacteria were less sensitive toward the tested compounds 6a-u than Gram-negative bacteria. Usually, increasing the lipophilic characteristic of the synthesized compound increases the antibacterial activity on Gram-positive bacteria. This can be explained on the bases of the low lipid content of the cell wall of Gram-positive bacteria, which would permit the activity of more lipophilic compounds [32]. Only compounds 6h-n, bearing the 4-chlorophenyl moiety, exhibited good activity against the tested standard Staphylococcus aureus as it showed MIC values of 250-1000 µg/mL. Furthermore, compounds 6b-g bearing phenyl moiety on the triazole ring showed MIC values of 250-500 µg/mL against Bacillus subtilis being similar to or better than the MIC value of the reference drug ampicillin (500 µg/mL). In contrast, compounds with N-4-chlorophenyl or N-cyclohexyl substituents did not show activity against Bacillus subtilis in the DIZ assay (Table 1). It was noticed that in general, the unsubstituted benzyl derivatives 6a, 6h, and 6o exhibited lower antibacterial activity against both Gram-negative and Gram-positive bacteria, which indicates the importance of the para substitution in the benzyl moiety.
The in vitro antifungal activity of the target compounds 6a-u is presented in Table 2. They displayed potent in vitro antifungal activity against Candida tropicalis with an MIC value as low as 2 µg/mL. Moreover, compounds 6a-g bearing N-phenyl substituent showed a DIZ value around 27 mm against the tested Candida albicans strain. Most of compounds 6a-g exhibited MIC value of 250 µg/mL being equal to that of the reference drug fluconazole except for compound 6f bearing 3, 4-dichlorbenzyl moiety, which revealed a potent MIC value of 2 µg/mL. Meanwhile, compounds 6o-u with N-cyclohexyl substituent displayed moderate to good activity against the tested Candida albicans strain, in which compounds 6p, 6q, and 6r are the most active congeners with an MIC value of 32 µg/mL. In addition, compounds 6a-g exhibited MIC values of 125-1000 µg/mL against Candida glabrata in which compound 6d was the most active candidate. Furthermore, compounds 6s (bearing 2,4-dichlorobenzyl and N-cyclohexyl substituents), 6t (bearing 3,4-dichlorobenzyl and N-cyclohexyl substituents), and 6u (bearing 4-methylbenzyl and N-cyclohexyl substituents) manifested good activity toward Candida glabrata with MIC values of 62.5, 32, and 16 µg/mL, respectively. Unexpectedly, the presence of 4-chlorophenyl moiety on the triazole ring of compounds 6h-n seems to be unfavorable for their activities against both Candida albicans and Candida glabrata. In addition, the influence of the para benzyl substituent in increasing the antifungal activity can be detected from the lower antifungal activity of the unsubstituted benzyl derivatives 6a and 6b.
The in vitro antifungal activity of the target compounds 6a-u against most of the tested fungal strains was generally higher than their antibacterial activity. This could be attributed to the presence of the triazole ring in their scaffold, which is consistent with the presence of the triazole ring in a number of clinically used antifungal agents [33].

3. Experimental

3.1. General

The melting points were measured using a Gallenkamp melting point device and are uncorrected. The NMR samples of the synthesized compounds 6a-u were dissolved in DMSO-d6 and the NMR spectra were recorded using a Bruker NMR spectrometer (Bruker, Reinstetten, Germany) at 500 MHz for 1H and 125.76 MHz for 13C at the Research Center, College of Pharmacy, King Saud University, Saudi Arabia. TMS was used as an internal standard, and chemical shift values were recorded in ppm on the δ scale. The 1H NMR spectral data are represented as follows: chemical shifts, multiplicity (s, singlet; d, doublet; t, triplet; m, multiplet) and number of protons. The 13C NMR spectral data were represented as chemical shifts and type of carbon. Mass spectra were measured on an Agilent Quadrupole 6120 LC/MS with ESI (electrospray ionization) source (Agilent Technologies, Palo Alto, CA, USA). Elemental analysis was carried out at the Microanalysis Laboratory, Cairo University, Cairo, Egypt, using an Elemental C, H, N analyzer Vario EL III, Germany, and the results agreed favorably with the proposed structures within ± 0.4% of the theoretical values. Silica gel thin layer chromatography (TLC) plates from Merck (silica gel precoated aluminium plates with fluorescent indicator at 254 nm) were used for thin layer chromatography. Visualization was performed by illumination with a UV light source (254 nm). The microanalysis data, 1HNMR and 13CNMR of compound 6d are also available in the Supplementary Materials.

3.2. Chemistry

3.2.1. Synthesis of Ethyl 1H-Indole-2-Carboxylate (2)

1H-indole-2-carboxylic acid was subjected to esterification in absolute ethanol and a catalytic amount of sulfuric acid according to the reported method. The crude ester 2 was used in the next step without further purification [34,35].

3.2.2. Synthesis of 1H-Indole-2-Carbohydrazide (3)

Compound 2 (0.875 g, 5 mmol) was suspended in absolute ethanol (10 mL), and hydrazine hydrate (2.5 mL, 50 mmol) was added. The reaction mixture was subjected to reflux for six hours under stirring. The reaction mixture was cooled to ambient temperature. The precipitated solid was filtered and dried to afford the carbohydrazide 3 [34,36].

3.2.3. General Procedure for the Synthesis of the Indole-1H-2-yl-4-Substituted-Thiosemicarbazides (4a-c)

A mixture of 1H-indole-2-carbohydrazide (3, 6 mmol) and the appropriate isothiocyanate (6 mmol) in absolute ethanol (10 mL) was heated under reflux for five hours, cooled, the precipitated solid was filtered off and dried to give the thiosemicarbazides 4a-c [34], which were used without further purification [31].

3.2.4. General Procedure for the Synthesis of 5-(1H-Indol-2-yl)-4-Substituted-1,2,4-Triazole-3-Thiols (5a-c)

Aqueous 10% NaOH (3.3 mL) was added to the appropriate thiosemicarbazide derivative 4a-c (10 mmol). The reaction mixture was heated to reflux for three hours, cooled, and neutralized with 5N HCl. The precipitated products 5a-c [34] were collected by filtration and re-crystallized from ethanol [31].

3.2.5. General Procedure for the Synthesis of the Target Compounds 6a-u

The appropriate benzyl halide (1.1 mmol) was added dropwise to a stirred suspension of the appropriate triazole derivative 5a-c (1 mmol) and anhydrous potassium carbonate (1.1 mmol) in dry acetone (15 mL). The reaction mixture was heated to reflux under stirring for two hours. The corresponding alkylated indoles 6a-u were collected by filtration and recrystallized from ethanol [37].
2-(5-(Benzylthio)-4-phenyl-4H-1,2,4-triazol-3-yl)-1H-indole (6a) [34]. White powder m.p. 250 °C (yield 99%); IR (KBr): ν (cm−1) 3163 (NH), 3061 (C-H, aromatic), 2980 (C-H, aliphatic), 1577, 1570 (C=N), 1494, 1450, 701; 1H NMR (DMSO-d6) ppm: 4.42 (s, 2H, CH2), 5.58 (d, J = 2.1 Hz, 1H, H-3), 6.94-6.96 (m, 1H, Har.), 7.14-7.15 (m, 1H, Har.), 7.27-7.29 (m, 1H, Har.), 7.30-7.31 (m, 2H, Har.), 7.34-7.36 (m, 3H, Har.), 7.39-7.40 (m, 2H, Har.), 7.43-7.44 (m, 1H, Har.), 7.62-7.64 (m, 2H, Har.), 7.67-7.69 (m, 1H, Har.), 12.01 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 37.11 (-S-CH2), 101.8, 112.3, 120.2, 121.2, 123.6, 124.3, 127.6, 128.0, 128.4, 128.9, 129.5, 130.6, 131.1, 134.1, 136.9, 137.4, 149.6, 151.7 (Car., CHar., CN); MS m/z (ESI): 383.2 [M + H]+.
2-(5-(4-Nitrobenzylthio)-4-phenyl-4H-1,2,4-triazol-3-yl)-1H-indole (6b). Yellow powder m.p. 271 °C (yield 90%); IR (KBr): ν (cm−1) 3147 (NH), 3061 (C-H, aromatic), 2987 (C-H, aliphatic), 1597, 1590 (C=N), 1516, 1338 (NO2), 1490, 1309, 800; 1H NMR (DMSO-d6) ppm: 4.55 (s, 2H, CH2), 5.59 (s, 1H, H-3), 6.94-6.96 (m, 1H, Har.), 7.13-7.15 (m, 1H, Har.), 7.35 (d, J = 7.7 Hz, 1H, Har.), 7.43-7.44 (m, 1H, Har.), 7.48 (d, J = 7.7 Hz, 2H, Har.), 7.64-7.70 (m, 5H, Har.), 8.18 (d, J = 8.4 Hz, 2H, Har.), 11.99 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 35.8 (-S-CH2), 101.9, 112.3, 120.2, 121.2, 123.6, 124.0, 124.2, 127.6, 128.4 130.7, 130.8, 131.2, 134.0, 136.9, 146.0, 147.1, 149.8, 151.3 (Car., CHar.); MS m/z (ESI): 428.1 [M+H]+.
4-((5-(1H-Indol-2-yl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)methyl)benzonitrile (6c). White powder m.p. 252 °C (yield 90%); IR (KBr): ν (cm−1) 3273 (NH), 3100 (C-H, aromatic), 2980 (C-H, aliphatic), 2227 (CN), 1595, 1590 (C=N), 1494, 1450, 700; 1H NMR (DMSO-d6) ppm: 4.49 (s, 2H, CH2), 5.59 (d, J = 1.4 Hz, 1H, H-3), 6.94-6.96 (m, 1H, Har.), 7.14 (t, J = 7.7 Hz, 1H, Har.), 7.35 (d, J = 8.4 Hz, 1H, Har.), 7.44 (d, J = 8.4 Hz, 1H, Har.), 7.47 (d, J = 8.4 Hz, 2H, Har.), 7.59 (d, J = 8.4 Hz, 2H, Har.), 7.64-7.66 (m, 2H, Har.), 7.68-7.70 (m, 1H, Har.), 7.79 (d, J = 8.4 Hz, 2H, Har.), 11.99 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 36.2 (-S-CH2), 101.9, 110.6, 112.3, 119.2, 120.2, 121.2, 123.6, 124.2, 127.6, 128.4, 130.5, 130.7, 131.2, 132.8, 134.0, 136.9, 143.8, 149.8, 151.4 (Car., CHar., CN); MS m/z (ESI): 405.9 [M-H]−.
2-(5-(4-Chlorobenzylthio)-4-phenyl-4H-1,2,4-triazol-3-yl)-1H-indole (6d). White powder m.p. 257 °C (yield 90%); IR (KBr): ν (cm−1) 3242 (NH), 3100 (C-H, aromatic), 2808 (C-H, aliphatic), 1600, 1597 (C=N), 1400, 1195, 700; 1H NMR (DMSO-d6) ppm: 4.41 (s, 2H, CH2), 5.58 (d, J = 1.4, 1H, H-3), 6.94-6.96 (m, 1H, Har.), 7.13-7.15 (m, 1H, Har.), 7.35 (d, J = 8.4, 1H, 1H, Har.), 7.37-7.40 (m, 4H, Har.), 7.43-7.45 (m, 3H, Har.), 7.65 (t, J = 7.7 Hz, 2H, Har.), 7.68-7.70 (m, 1H, Har.), 11.98 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 36.0 (-S-CH2), 101.9, 112.3, 120.2, 121.2, 123.6, 124.3, 127.6, 128.4, 128.9, 130.7, 131.2, 131.4, 132.6, 134.1, 136.8, 136.9, 149.7, 151.6 (Car., CHar.); MS m/z (ESI): 415.7 [M-H]−, 417 [(M + 2)-H]−.
2-(5-(2,4-Dichlorobenzylthio)-4-phenyl-4H-1,2,4-triazol-3-yl)-1H-indole (6e). White powder m.p. 255 °C (yield 99%); IR (KBr): ν (cm−1) 3250 (NH), 3111 (C-H, aromatic), 2935 (C-H, aliphatic), 1600, 1597 (C=N), 1496, 1398, 800; 1H NMR (DMSO-d6) ppm: 4.45 (s, 2H, CH2), 5.59 (s, 1H, H-3), 6.94-6.96 (m, 1H, Har.), 7.13-7.15 (m, 1H, Har.), 7.35 (d, J = 7.7 Hz, 1H, Har.), 7.41 (dd, J = 7.7, 2.1 Hz, 1H, Har.), 7.43 (d, J = 7.7 Hz, 1H, Har.), 7.46 (d, J = 7 Hz, 2H, Har.), 7.54 (d, J = 8.4 Hz, 1H, Har.), 7.64-6.66 (m, 3H, Har.), 7.69 (t, J = 7.7 Hz, 1H, Har.), 12.00 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 34.7 (-S-CH2), 101.9, 112.3, 120.2, 121.2, 123.7, 124.2, 127.6, 127.9, 128.4, 129.5, 130.7, 131.2, 133.2, 133.7, 134.0, 134.2, 134.7, 136.9, 149.9, 150.9 (Car., CHar.); MS m/z (ESI): 448.8 [M-H]−, 450.8 [(M + 2)-H]−, 452.9 [(M + 4)-H]−.
2-(5-(3,4-Dichlorobenzylthio)-4-phenyl-4H-1,2,4-triazol-3-yl)-1H-indole (6f). White powder m.p. 215 °C (yield 88%); IR (KBr): ν (cm−1) 3207 (NH), 3057 (C-H, aromatic), 2918 (C-H, aliphatic), 1597, 1566 (C=N), 1496, 1398, 700; 1H NMR (DMSO-d6) ppm: 4.41 (s, 2H, CH2), 5.59 (s, 1H, H-3), 6.95 (t, J = 7.7 Hz, 1H, Har.), 7.13-7.15 (m, 1H, Har.), 7.35-7.38 (m, 2H, Har.), 7.43 (d, J = 8.4 Hz, 1H, Har.), 7.47 (d, J = 7.7 Hz, 2H, Har.), 7.58 (d, J = 8.4 Hz, 2H, Har.), 7.64-7.66 (m, 2H, Har.), 7.68-7.70 (m, 2H, Har.), 12.00 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 35.41 (-S-CH2), 101.9, 112.3, 120.2, 121.2, 123.6, 124.2, 127.6, 128.4, 129.8, 130.5, 130.7, 131.0, 131.2, 131.3, 131.6, 134.0, 136.9, 139.3, 149.9, 151.4 (Car., CHar.); MS m/z (ESI): 448.8 [M-H]−, 450.8 [(M + 2)-H]−, 452.5 [(M + 4)-H]−.
2-(5-((4-Methylbenzyl)thio)-4-phenyl-4H-1,2,4-triazol-3-yl)-1H-indole (6g): White powder m.p. 274 °C (yield 95%); IR (KBr): ν (cm−1) 3336 (NH), 3111 (C-H, aromatic), 2933 (C-H, aliphatic), 1647,1630 (C=N), 1436, 1344, 701; 1H NMR (DMSO-d6) ppm: 2.28 (s, 3H, CH3), 4.37 (s, 2H, CH2), 5.57 (s, 1H, H-3), 6.95 (t, J = 7.7 Hz, 1H, Har.), 7.11-7.13 (m, 3H, Har.), 7.22 (d, J = 7.7 Hz, 2H, Har.), 7.35 (d, J = 7.7 Hz, 1H, Har.), 7.40 (d, J = 7 Hz, 2H, Har.), 7.43 (d, J = 8.4 Hz, 1H, Har.), 7.63-7.65 (m, 2H, Har.), 7.67-7.69 (m, 1H, Har.), 12.00 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 21.1 (CH3), 36.9 (-S-CH2), 101.7, 112.3, 120.2, 121.2, 123.6,124.3, 127.6, 128.4, 129.4, 129.5, 130.6, 131.1, 134.1, 134.3, 136.9, 137.3, 149.6, 151.8 (Car., CHar.); MS m/z: 394.9 [M-H]−.
2-(5-(Benzylthio)-4-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl)-1H-indole (6h): beige powder m.p. 245 °C (yield 70%); IR (KBr): ν (cm−1) 3147 (NH), 3089 (C-H, aromatic), 2924 (C-H, aliphatic), 1595, 1571 (C=N), 1494, 1436, 800, 701; 1H NMR (DMSO-d6) ppm: 4.41 (s, 2H, CH2), 5.67 (s, 1H, H-3), 6.96 (t, J = 7 Hz, 1H, Har.), 7.15 (t, J = 7 Hz, 1H, Har.), 7.27-7.29 (m, 1H, Har.), 7.31-7.32 (m, 4H, Har.), 7.41-7.44 (m, 2H, Har.), 7.46 (d, J = 8.4 Hz, 2H, Har.), 7.70 (d, J = 8.4 Hz, 2H, Har.), 11.99 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 37.3 (-S-CH2), 102.0, 112.3, 120.2, 121.3, 123.6, 124.1, 127.6, 128.1, 128.9, 129.5, 130.4, 130.7, 133.0, 135.7, 136.9, 137.4, 149.5, 151.7 (Car., CHar.); MS m/z: 414.9 [M-H]−, 416.9 [(M + 2)-H]−.
2-(5-(4-Nitrobenzylthio)-4-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl)-1H-indole (6i). Yellow powder m.p. 217 °C (yield 82%); IR (KBr): ν (cm−1) 3248 (NH), 3103 (C-H, aromatic), 2924 (C-H, aliphatic), 1598, 1471 (C=N), 1492, 1350 (NO2), 800, 701; 1H NMR (DMSO-d6) ppm: 4.53 (s, 2H, CH2), 5.69 (s, 1H, H-3), 6.96 (t, J = 7.7 Hz, 1H, Har.), 7.15 (t, J = 7.7 Hz, 1H, Har.), 7.42 (d, J = 8.4 Hz, 2H, Har.), 7.55(d, J = 9.1 Hz, 2H, Har.), 7.66 (d, J = 8.4 Hz, 2H, Har.), 7.72 (d, J = 8.4 Hz, 2H, Har.), 8.18 (d, J = 8.4 Hz, 2H, Har.), 11.97 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 36.0 (-S-CH2), 102.0, 112.3, 120.2, 121.3, 123.7, 124.0, 127.6, 130.4, 130.7, 130.8, 132.9, 135.8, 136.9, 145.9, 147.2, 149.7, 151.2, 207.1 (Car., CHar.); MS m/z: 462.9 [M+H]+.
4-((4-(4-Chlorophenyl)-5-(1H-indol-2-yl)-4H-1,2,4-triazol-3-ylthio)methyl)benzonitrile (6j): Pale Yellow powder m.p. 190 °C (yield 67%); IR (KBr): ν (cm−1) 3354 (NH), 3091 (C-H, aromatic), 2920 (C-H, aliphatic), 2225 (CN), 1598, 1590 (C=N), 1498, 1454, 800, 701; 1H NMR (DMSO-d6) ppm: 4.48 (s, 2H, CH2), 5.69 (s, 1H, H-3), 6.96 (t, J = 7.7 Hz, 1H, Har.), 7.15 (t, J = 7.7 Hz, 1H, Har.), 7.43 (d, J = 8.4 Hz, 2H, Har.), 7.54 (d, J = 8.4 Hz, 2H, Har.), 7.58 (d, J = 7.7 Hz, 2H, Har.), 7.70 (d, J = 7.70 Hz, 1H, Har.), 7.73 (d, J = 9.1 Hz, 2H, Har.), 7.79 (d, J = 7.7 Hz, 2H, Har.), 11.97 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 36.0 (-S-CH2), 102.0, 112.3, 120.3, 121.4, 123.8, 124.1, 127.7, 130.4, 130.5, 130.8, 132.9, 133.1, 133.2, 133.7, 135.9, 136.8, 143.9, 149.6, 151.5 (Car., CHar., CN); MS m/z: 439.9 [M-H]−, 442 [(M + 2)-H]−.
2-(5-(4-Chlorobenzylthio)-4-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl)-1H-indole (6k): Yellow powder m.p. 235 °C (yield 37%); IR (KBr): ν (cm−1) 3178 (NH), 3032 (C-H, aromatic), 2918 (C-H, aliphatic), 1490, 1400 (C=N), 1350, 800, 701; 1H NMR (DMSO-d6) ppm: 4.40 (s, 2H, CH2), 5.69 (s, 1H, H-3), 6.95-6.97 (m, 1H, Har.), 7.15 (t, J = 7.7 Hz, 1H, Har.), 7.37-7.40 (m, 4H, Har.), 7.42-7.44 (m, 2H, Har.), 7.52 (d, J = 8.4 Hz, 2H, Har.), 7.72 (d, J = 8.4 Hz, 2H, Har.) 11.99 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 36.2 (-S-CH2), 102.0, 112.3, 120.2, 121.3, 123.7, 124.1, 127.6, 128.9, 130.4, 130.8, 131.4, 132.6, 132.9, 135.8, 136.7, 136.9, 149.5, 151.5 (Car., CHar.); MS m/z (ESI): 450.8 [M-H]−, 452.7 [(M + 2)-H]−, 454 [(M + 4)-H]−.
2-(5-(2,4-Dichlorobenzylthio)-4-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl)-1H-indole (6l): White powder m.p. 239 °C (yield 79%); IR (KBr): ν (cm−1) 3155 (NH), 3091 (C-H, aromatic), 2922 (C-H, aliphatic), 1591, 1580 (C=N), 1490, 1388, 800, 701. 600; 1H NMR (DMSO-d6) ppm: 4.43 (s, 2H, CH2), 5.70 (s, 1H, H-3), 6.96 (t, J = 7.7 Hz, 1H, Har.), 7.14-7.16 (m, 1H, Har.), 7.40-7.42 (dd, J =8.4, 2.1 Hz, 1H, Har.), 7.43 (d, J = 7.7 Hz, 2H, Har.), 7.53-7.57 (m, 3H, Har.), 7.64 (d, J = 2.1 Hz, 1H, Har.), 7.72-7.73 (m, 2H, Har.), 12.00 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 34.8 (-S-CH2), 102.13, 112.3, 120.2, 121.3, 123.7, 124.1, 127.6, 127.9, 129.5, 130.4, 130.4, 130.7, 132.9, 133.2, 133.7, 134.7, 135.8, 137.0, 149.8, 150.8 (Car., CHar.); MS m/z (ESI): 482.8 [M-H]−, 484.8 [(M + 2) + H]+, 486.8 [(M+4)-H]−, 488.7 [(M+6)-H]−.
2-(5-(3,4-Dichlorobenzylthio)-4-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl)-1H-indole (6m): Beige powder m.p. 229 °C (yield 83%); IR (KBr): ν (cm−1) 3251 (NH), 3053 (C-H, aromatic), 2922 (C-H, aliphatic), 1620, 1597 (C=N), 1496, 1342, 800, 701, 600; 1H NMR (DMSO-d6) ppm: 4.39 (s, 2H, CH2), 5.70 (s, 1H, H-3), 6.96 (t, J = 7 Hz, 1H, Har.), 7.15 (t, J = 7 Hz, 1H, Har.), 7.36-7.38 (m, 1H, Har.), 7.43 (d, J = 7 Hz, 2H, Har.), 7.55-7.67 (m, 3H, Har.), 7.67 (s, 1H, Har.), 7.72-7.73 (m, 2H, Har.), 12.00 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 35.7 (-S-CH2), 102.1, 112.3, 120.2, 121.3, 123.7, 124.1, 127.6, 129.8, 130.4, 130.5, 130.7, 131.0, 131.3, 131.5, 132.9, 135.8, 137.0, 139.2, 149.7, 151.3 (Car., CHar.,CClar); MS m/z (ESI): 482.8 [M-H]−, 484.8 [(M + 2) + H]+, 486.8 [(M+4)-H]−, 488.7 [(M+6)-H]−.
2-(4-(4-Chlorophenyl)-5-((4-methylbenzyl)thio)-4H-1,2,4-triazol-3-yl)-1H-indole (6n): Yellow powder m.p. 295 °C (yield 80%); IR (KBr): ν (cm−1) 3203 (NH), 3061 (C-H, aromatic), 2918 (C-H, aliphatic), 1685, 1577 (C=N), 1492, 1346, 800, 701; 1H NMR (DMSO-d6) ppm: 2.10 (s, 3H, CH3), 4.36 (s, 2H, CH2), 5.68 (s, 1H, H-3), 6.95-6.97 (m, 1H, Har.), 7.12 (d, J = 7.7 Hz, 2H, Har.), 7.15 (t, J = 7.7 Hz, 1H, Har.), 7.21 (d, J = 8.4 Hz, 2H, Har.), 7.42-7.46 (m, 4H, Har.), 7.71 (d, J = 9.1 Hz, 2H, Har.), 12.00 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 21.18 (CH3), 37.1 (-S-CH2), 101.9, 112.3, 120.2, 121.3, 123.7, 124.1, 127.6, 127.9, 129.5, 130.4, 130.7, 133.0, 134.2, 135.7, 136.9, 137.3, 149.5, 151.7, (Car., CHar.); MS m/z: 428.8 [M-H]+, 430.9 [(M + 2)-H]−
2-(5-(Benzylthio)-4-cyclohexyl-4H-1,2,4-triazol-3-yl)-1H-indole (6o): White powder m.p. > 300 °C (yield 84%); IR (KBr): ν (cm−1) 3448 (NH), 3138 (C-H, aromatic), 2939 (C-H, aliphatic), 1676, 1660 (C=N), 1571, 1460, 701; 1H NMR (DMSO-d6) ppm: 1.05-1.11 (m, 1H, cyclohexyl), 1.26-1.32 (m, 2H, cyclohexyl), 1.60 (d, J = 13.3 Hz, 1H, cyclohexyl), 1.76 (s, 4H, cyclohexyl), 1.97-2.03 (m, 2H, cyclohexyl), 4.34-4.38 (m, 1H, cyclohexyl), 4.56 (s, 2H, CH2), 6.75 (s, 1H, H-3), 7.07-7.09 (m, 1H, Har.), 7.19-7.22 (m, 1H, Har.), 7.28-7.30 (m, 1H, Har.), 7.33-7.35 (m, 2H, Har.), 7.43 (d, J = 7 Hz, 2H, Har), 7.47 (d, J = 7.7 Hz, 1H, Har.), 7.65 (d, J = 8.4 Hz, 1H, Har.), 11.83 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 24.9, 25.7, 31.1(cyclohexyl), 37.7 (-S-CH2), 56.7 (cyclohexyl), 103.6, 112.3, 120.2, 121.3, 123.4, 124.2, 127.9, 128.0, 128.9, 129.5, 136.9, 137.4, 149.7, 149.8 (Car., CHar); MS m/z: 386.9 [M-H]−.
2-(5-(4-Nitrobenzylthio)-4-cyclohexyl-4H-1,2,4-triazol-3-yl)-1H-indole (6p): Yellow powder m.p. 255 °C (yield 59%); IR (KBr): ν (cm−1) 3165 (NH), 3090 (C-H, aromatic), 2931 (C-H, aliphatic), 1618, 1598 (C=N), 1517, 1346 (NO2), 1444, 1436, 701; 1H NMR (DMSO-d6) ppm: 1.08-1.14 (m, 1H, cyclohexyl), 1.28-1.34 (m, 2H, cyclohexyl), 1.62 (d, J = 13.3 Hz, 1H, cyclohexyl), 1.78-1.79 (m, 4H, cyclohexyl), 1.97-2.03 (m, 2H, cyclohexyl), 4.35-4.39 (m, 1H, cyclohexyl), 4.70 (s, 2H, CH2), 6.78 (s, 1H, H-3), 7.07-7.09 (m, 1H, Har.), 7.20-7.22 (m, 1H, Har.), 7.47 (d, J = 8.4 Hz, 1H, Har.), 7.65 (d, J = 7.7 Hz, 1H, Har.), 7.74 (d, J = 9.1 Hz, 2H, Har), 8.21 (d, J = 8.4 Hz, 2H, Har.), 11.83 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 24.9, 25.7, 31.1 (cyclohexyl), 36.5 (-S-CH2), 56.7 (cyclohexyl), 103.7, 112.3, 120.2, 121.3, 123.4, 124.0, 124.1, 127.9, 130.8, 136.9, 146.1, 147.2, 149.1, 150.1 (Car., CHar); MS m/z: 431.9 [M-H]−.
4-((4-Cyclohexyl-5-(1H-indol-2-yl)-4H-1,2,4-triazol-3-ylthio)methyl)benzonitrile (6q): White powder m.p. 235 °C (yield 56%); IR (KBr): ν (cm−1) 3192 (NH), 3057 (C-H, aromatic), 2970 (C-H, aliphatic), 2225 (CN), 1685, 1606 (C=N), 1436, 701; 1H NMR (DMSO-d6) ppm: 1.10-1.12 (m, 1H, cyclohexyl), 1.29-1.34 (m, 2H, cyclohexyl), 1.62 (d, J = 12.6 Hz, 1H, cyclohexyl), 1.78 (d, J = 10.5 Hz, 4H, cyclohexyl), 1.96-2.02 (m, 2H, cyclohexyl), 4.37-4.38 (m, 1H, cyclohexyl), 4.65 (s, 2H, CH2), 6.78 (s, 1H, H-3), 7.07-7.09 (m, 1H, Har.), 7.20-7.22 (m, 1H, Har.), 7.46 (d, J = 8.4 Hz, 1H, Har.), 7.65-7.67 (m, 3H, Har.), 7.82 (d, J = 8.4 Hz, 2H, Har), 11.83 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 24.9, 25.7, 31.1 (cyclohexyl), 36.8 (-S-CH2), 56.7 (cyclohexyl), 103.6, 110.59 112.3, 119.2, 120.3, 121.4, 123.4, 124.1, 127.9, 130.5, 132.8, 136.9, 143.9, 149.1, 150.1 (Car., CHar); MS m/z: 411.9 [M-H]−.
2-(5-(4-Chlorobenzylthio)-4-cyclohexyl-4H-1,2,4-triazol-3-yl)-1H-indole (6r): White powder m.p. 250 °C (yield 85%); IR (KBr): ν (cm−1) 3176 (NH), 3055 (C-H, aromatic), 2931 (C-H, aliphatic), 1589, 1580 (C=N), 1494, 1438, 800, 701; 1H NMR (DMSO-d6) ppm: 1.07-1.13 (m, 1H, cyclohexyl), 1.28-1.34 (m, 2H, cyclohexyl), 1.61 (d, J = 13.3 Hz, 1H, cyclohexyl), 1.78 (d, J = 10.5 Hz, 4H, cyclohexyl), 1.97-2.03 (m, 2H, cyclohexyl), 4.35-4.39 (m, 1H, cyclohexyl), 4.56 (s, 2H, CH2), 6.79 (s, 1H, H-3), 7.07-7.09 (m, 1H, Har.), 7.20-7.22 (m, 1H, Har.), 7.41 (d, J = 8.4 Hz, 2H, Har.), 7.47-7.48 (m, 3H, Har.), 7.66 (d, J = 8.4 Hz, 1H, Har), 11.83 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 24.9, 25.7, 31.1 (cyclohexyl), 36.7 (-S-CH2), 56.7 (cyclohexyl), 103.6, 112.3, 120.2, 121.3, 123.4, 124.2, 127.9, 128.9, 131.4, 132.6, 136.9, 137.0, 149.5, 149.9 (Car., CHar); MS m/z (ESI): 420.9 [M-H]−, 422.9 [(M + 2)-H]−.
2-(5-(2,4-Dichlorobenzylthio)-4-cyclohexyl-4H-1,2,4-triazol-3-yl)-1H-indole (6s): Yellow powder m.p. 200 °C (yield 60%); IR (KBr): ν (cm−1) 3288 (NH), 3078 (C-H, aromatic), 2927 (C-H, aliphatic), 1570, 1560 (C=N), 1467, 1436, 800, 750, 701; 1H NMR (DMSO-d6) ppm: 1.07-1.13 (m, 1H, cyclohexyl), 1.28-1.34 (m, 2H, cyclohexyl), 1.61 (d, J = 12.6 Hz, 1H, cyclohexyl), 1.77 (s, 4H, cyclohexyl), 1.95-2.01 (m, 2H, cyclohexyl), 4.34-4.39 (m, 1H, cyclohexyl), 4.61 (s, 2H, CH2), 6.79 (s, 1H, H-3), 7.07-7.09 (m, 1H, Har.), 7.20-7.22 (m, 1H, Har.), 7.42 (dd, J = 8.4, 2.1 Hz, 1H, Har.), 7.47 (d, J = 7.7 Hz, 1H, Har.), 7.55 (d, J = 8.4 Hz, 1H, Har), 7.66-7.68 (m, 1H, Har.), 7.70 (d, J = 2.1 Hz, 1H, Har.), 11.84 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 24.9, 25.7, 31.2 (cyclohexyl), 35.5 (-S-CH2), 56.8 (cyclohexyl), 103.6, 112.3, 120.2, 121.3, 123.4, 124.1, 127.9, 129.5, 133.2, 133.8, 134.1, 134.8, 136.9, 148.9, 149.9 (Car., CHar); MS m/z (ESI): 454.9 [M-H]−, 456.8 [(M + 2)-H]−, 458.9 [(M + 4)-H]−.
2-(5-(3,4-Dichlorobenzylthio)-4-cyclohexyl-4H-1,2,4-triazol-3-yl)-1H-indole (6t): Yellow powder m.p. 202 °C (yield 53%); IR (KBr): ν (cm−1) 3186 (NH), 3086 (C-H, aromatic), 2935 (C-H, aliphatic), 1577, 1540 (C=N), 1494, 1436, 800, 760, 701; 1H NMR (DMSO-d6) ppm: 1.10-1.14 (m, 1H, cyclohexyl), 1.30-1.35 (m, 2H, cyclohexyl), 1.62 (d, J = 12.6 Hz, 1H, cyclohexyl), 1.79 (d, J = 11.2 Hz, 4H, cyclohexyl), 1.98-2.02 (m, 2H, cyclohexyl), 4.36-4.40 (t, J = 12.6 Hz, 1H, cyclohexyl), 4.57 (s, 2H, CH2), 6.79 (s, 1H, H-3), 7.07-7.09 (m, 1H, Har.), 7.20-7.22 (m, 1H, Har.), 7.45-7.47 (m, 2H, Har.), 7.61 (d, J = 8.4 Hz, 1H, Har.), 7.66 (d, J = 8.4 Hz, 1H, Har), 7.75 (d, J = 2.1 Hz, 1H, Har.), 11.84 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 24.9, 25.7, 31.1 (cyclohexyl), 36.09 (-S-CH2), 56.8 (cyclohexyl), 103.6, 112.3, 120.2, 121.4, 123.4, 124.1, 127.9, 129.9, 130.5, 131.0, 131.3, 131.6, 137.0, 139.3, 149.3, 150.0 (Car., CHar); MS m/z (ESI): 454.9 [M-H]−, 456.8 [(M + 2)-H]−, 458.9 [(M + 4)-H]−.
2-(4-Cyclohexyl-5-((4-methylbenzyl)thio)-4H-1,2,4-triazol-3-yl)-1H-indole (6u): Yellow powder m.p. 190 °C (yield 84%); IR (KBr): ν (cm−1) 3200 (NH), 3055 (C-H, aromatic), 2922 (CH, aliphatic), 1637,1640 (C=N), 1494, 1436, 800, 700; 1H NMR (DMSO-d6) ppm: 1.07-1.12 (m, 1H, cyclohexyl), 1.27-1.33 (m, 2H, cyclohexyl), 1.61 (d, J = 12.5 Hz, 1H, cyclohexyl), 1.77 (d, J = 11.2 Hz, 4H, cyclohexyl), 1.98-2.04 (m, 2H, cyclohexyl), 2.28 (s, 3H, CH3), 4.35-4.39 (m, 1H, cyclohexyl), 4.52 (s, 2H, CH2), 6.79 (s, 1H, H-3), 7.07-7.09 (m, 1H, Har.), 7.15 (d, J = 7.7 Hz, 2H, Har.), 7.19-7.22 (m, 1H, Har.), 7.33 (d, J = 7.7 Hz, 2H, Har.), 7.47 (d, J = 8.4 Hz, 1H, Har), 7.66 (d, J = 8.4 Hz, 1H, Har), 11.84 (s, 1H, NH); 13C NMR (DMSO-d6) ppm: 21.2 (CH3), 24.9, 25.7, 31.1 (cyclohexyl), 37.52 (-S-CH2), 56.7 (cyclohexyl), 103.5, 112.3, 120.2, 121.3, 123.4, 124.3, 128.0, 129.5, 129.6, 134.3, 136.9, 137.3, 149.7, 149.8 (Car., CHar); MS m/z: 400.9 [M-H]−.

3.3. Antimicrobial Evaluation

3.3.1. Materials

Dimethyl sulfoxide (100%) was used to dissolve the standards ampicillin, fluconazole, and the tested compounds 6a-u to give an initial concentration of 1 mg/mL.

3.3.2. Organisms

All the tested strains bacterial and Candida in this study were provided from King Khaled University hospital, Microbiology Department. Bacterial strains were divided into Gram-positive bacteria namely Staphylococcus aureus (ATCC 25923), Bacillus subtilis (ATCC 6633). Escherichia coli (ATCC 25966). Pseudomonas aeruginosa (ATCC 27853) and Salmonella (LT2) as negative strains. Candida tropicalis (ATCC 66019), Candida glabrata (clinical isolates) and Candida albicans (ATCC10231) as fungal strains. All these microorganisms were pre-cultured on nutrient agar (Oxoid) and PDA (potato dextrose agar, Oxoid). Then, 0.5 McFarland turbidity of each microbial suspension was prepared in 5 mL nutrient broth tubes for the antibacterial assays (Agar well diffusion technique and MIC test).

3.3.3. Agar Well Diffusion Technique

The antimicrobial activity of the tested compounds was determined using the agar well diffusion method. The prepared microbial suspensions were loaded on the surface of Mueller Hinton (Oxoid) plates using a sterile cotton swab. The agar surface was perforated with a sterile cork borer (6mm), and 100 µL of each compound (1000 µg/mL) were transferred into each well correspondingly. Plates were incubated aerobically for 18-24 h at 37 °C. Diameters of the inhibition zones were measured around each well and were recorded in mm as average of triplicate trials. DMSO was used as a negative control, while ampicillin and fluconazole were used as positive controls [38].

3.3.4. MIC Test

The minimum inhibitory concentration of the synthesized compounds in the current study against the microbial strains was determined using the micro-broth dilution assay (MIC). The concentrations of the extracts used for MICs ranged from 100% (1mg/mL) to 0.25%. In brief, 100 µL of Mueller–Hinton broth (MH) was first loaded in polystyrene sterile flat-bottom 96-well plates; then, 100 µL of each compound in study was added, and two fold dilutions were performed until the 0.25% concentration is reached; finally, 50 µL of each of the bacterial suspensions was loaded respectively. Plates were incubated at 37 °C for 18-24 hrs, following incubation plates that were read at 600 nm with an Elisa reader (Biotech). The first column of the 96-well plate was loaded with only with Mueller Hinton broth; the bacterial suspension was a positive control and the last column was the negative control consisting of the medium broth (MH) and the extract correspondingly. The lowest concentration of compounds where no visible bacterial growth was observed and recorded after 24 h of incubation was considered as the MIC. The experiments were repeated in triplicate [39].

4. Conclusions

A series of indole-1,2,4-triazole molecular hybrids 6a-u was synthesized and their structures were confirmed by different spectroscopic tools. Their in vitro antibacterial evaluation revealed that they possess good to moderate antibacterial activity against most of the tested Gram-negative strains with DIZ values in the range of 11-15 mm and MIC value around 250 µg/mL. Meanwhile, their antifungal evaluation showed higher activity especially against Candida tropicalis with MIC value as low as 2 µg/mL for most of the tested compounds. Moreover, compound 6f bearing N-phenyl and 3, 4-dichlorbenzyl moieties revealed a potent growth inhibition zone of 26 mm in the DIZ assay and MIC value of 2 µg/mL against Candida albicans. In addition, the antibacterial and the antifungal activities results imply the significance of the para benzyl substituent.

Supplementary Materials

The microanalysis data are available in Table S1 in the supplementary materials. 1HNMR and 13CNMR of compound 6d are also available in the supplementary materials.

Author Contributions

M.A.A. synthesized the target compounds 6a-u and carried out their spectroscopic identification. M.S.A.-M. contributed in the spectroscopic identification. S.I.B. and N.M.S.M. performed the in vitro antimicrobial evaluation of the synthesized compounds 6a-u. R.I.A.-W. and M.I.A. proposed the work and prepared the manuscript for publication. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Deanship of Scientific Research at King Saud University, Research Group Project No. RG-1440-140.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article or Supplementary Materials.

Acknowledgments

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding of this research through the Research Group Project No. RG-1440-140

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the synthesized compounds are available from the corresponding authors.

References

  1. Brown, G.D.; Denning, D.W.; Levitz, S.M. Tackling human fungal infections. Science 2012, 336, 647. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Roberts, R.R.; Hota, B.; Ahmad, L.; Scott, D.; Foster, S.D.; Abbasi, F.; Schabowski, S.; Kampe, L.M.; Gr-Ciavarella, G.; Supino, M.; et al. Hospital and societal costs of antimicrobial-resistant infections in a chicago teaching hospital: Implications for antibiotic stewardship. Clin. Infect. Dis. 2009, 49, 1175–1184. [Google Scholar] [CrossRef] [PubMed]
  3. Zhang, F.F.; Gan, L.L.; Zhou, C.H. Synthesis, antibacterial and antifungal activities of some carbazole derivatives. Bioorganic Med. Chem. Lett. 2010, 20, 1881–1884. [Google Scholar] [CrossRef] [PubMed]
  4. Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 2011, 52. [Google Scholar] [CrossRef] [PubMed]
  5. Kaku, N.; Morinaga, Y.; Takeda, K.; Kosai, K.; Uno, N.; Hasegawa, H.; Miyazaki, T.; Izumikawa, K.; Mukae, H.; Yanagihara, K. Antimicrobial and immunomodulatory effects of tedizolid against methicillin-resistant Staphylococcus aureus in a murine model of hematogenous pulmonary infection. Int. J. Med. Microbiol. 2016, 306, 421–428. [Google Scholar] [CrossRef] [PubMed]
  6. Inman, M.; Moody, C.J. Indole synthesis-something old, something new. Chem. Sci. 2013, 4, 29–41. [Google Scholar] [CrossRef]
  7. Berger, M.; Gray, J.A.; Roth, B.L. The expanded biology of serotonin. Annu. Rev. Med. 2009, 60, 355–366. [Google Scholar] [CrossRef] [Green Version]
  8. Sharma, V.; Kumar, P.; Pathaka, D. Biological importance of the indole nucleus in recent years: A comprehensive review. J. Heterocycl. Chem. 2010, 47, 491–502. [Google Scholar] [CrossRef]
  9. Zhang, M.Z.; Chen, Q.; Yang, G.F. A review on recent developments of indole-containing antiviral agents. Eur. J. Med. Chem. 2015, 89, 421–441. [Google Scholar] [CrossRef]
  10. Frost, J.M.; Dart, M.J.; Tietje, K.R.; Garrison, T.R.; Grayson, G.K.; Daza, A.V.; El-Kouhen, O.F.; Yao, B.B.; Hsieh, G.C.; Pai, M.; et al. Indol-3-ylcycloalkyl ketones: Effects of N1 substituted indole side chain variations on CB2 cannabinoid receptor activity. J. Med. Chem. 2010, 53, 295–315. [Google Scholar] [CrossRef]
  11. Rathod, A.S.; Godipurge, S.S.; Biradar, J.S. Microwave Assisted, Solvent-Free, “Green” Synthesis of Novel Indole Analogs as Potent Antitubercular and Antimicrobial Agents and Their Molecular Docking Studies. Russ. J. Gen. Chem. 2018, 88, 1238–1246. [Google Scholar] [CrossRef]
  12. Niemyjska, M.; MacIejewska, D.; Wolska, I.; Truszkowski, P. Synthesis, structural investigations, and anti-cancer activity of new methyl indole-3-carboxylate derivatives. J. Mol. Struct. 2012, 1026, 30–35. [Google Scholar] [CrossRef]
  13. Varvaresou, A.; Tsantili-Kakoulidou, A.; Siatra-Papastaikoudi, T.; Tiligada, E. Synthesis and biological evaluation of indole containing derivatives of thiosemicarbazide and their cyclic 1,2,4-triazole and 1,3,4-thiadiazole analogs. Arzneimittel-Forschung/Drug Res. 2000, 50, 48–54. [Google Scholar] [CrossRef] [PubMed]
  14. Pintilie, O.; Profire, L.; Sunel, V.; Popa, M.; Pui, A. Synthesis and Antimicrobial Activity of Some New 1,3,4-Thiadiazole and 1,2,4-Triazole Compounds Having a D,L-Methionine Moiety. Molecules 2007, 12, 103–113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Zou, X.J.; Lai, L.H.; Jin, G.Y.; Zhang, Z.X. Synthesis, fungicidal activity, and 3D-QSAR of pyridazinone-substituted 1,3,4-oxadiazoles and 1,3,4-thiadiazoles. J. Agric. Food Chem. 2002, 50, 3757–3760. [Google Scholar] [CrossRef] [PubMed]
  16. Chen, H.; Li, Z.; Han, Y. Synthesis and fungicidal activity against Rhizoctonia solani of 2-alkyl (alkylthio)-5-pyrazolyl-1,3,4-oxadiazoles (thiadiazoles). J. Agric. Food Chem. 2000, 48, 5312–5315. [Google Scholar] [CrossRef] [PubMed]
  17. Banu, K.M.; Dinakar, A.; Ananthanarayanan, C. Synthesis, characterization, antimicrobial studies and pharmacological screening of some substituted 1,2,3-triazoles. Indian J. Pharm. Sci. 1999, 61, 202–205. [Google Scholar]
  18. Keri, R.S.; Patil, S.A.; Budagumpi, S.; Nagaraja, B.M. Triazole: A Promising Antitubercular Agent. Chem. Biol. Drug Des. 2015, 86, 410–423. [Google Scholar] [CrossRef] [PubMed]
  19. Duran, A.; Dogan, H.N.; Rollas, S. Synthesis and preliminary anticancer activity of new 1,4-dihydro-3-(3-hydroxy-2-naphthyl)-4-substituted-5H-1,2,4-triazoline-5-thiones. Il Farm. 2002, 57, 559–564. [Google Scholar] [CrossRef]
  20. Gujjar, R.; Marwaha, A.; El Mazouni, F.; White, J.; White, K.L.; Creason, S.; Shackleford, D.M.; Baldwin, J.; Charman, W.N.; Buckner, F.S.; et al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J. Med. Chem. 2009, 52, 1864–1872. [Google Scholar] [CrossRef] [Green Version]
  21. Johns, B.A.; Weatherhead, J.G.; Allen, S.H.; Thompson, J.B.; Garvey, E.P.; Foster, S.A.; Jeffrey, J.L.; Miller, W.H. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. Bioorganic Med. Chem. Lett. 2009, 19, 1802–1806. [Google Scholar] [CrossRef] [PubMed]
  22. Schenone, S.; Bruno, O.; Ranise, A.; Bondavalli, F.; Filippelli, W.; Falcone, G.; Giordano, L.; Vitelli, M.R. 3-Arylsulphonyl-5-arylamino-1,3,4-thiadiazol-2(3H)ones as anti-inflammatory and analgesic agents. Bioorg. Med. Chem. 2001, 9, 2149–2153. [Google Scholar] [CrossRef]
  23. Ghodhani, D.R.; Jogel, A.A.; Sanghani, A.M.; Jignasu, P.M. Synthesis and biological screening of 1,2,4-triazole derivatives. Indian J. Chem. 2015, 54B, 556–564. [Google Scholar]
  24. Viegas-Junior, C.; Danuello, A.; da Silva Bolzani, V.; Barreiro, E.J.; Fraga, C.A.M. Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes. Curr. Med. Chem. 2007, 14, 1829–1852. [Google Scholar] [CrossRef]
  25. Shirinzadeh, H.; Süzen, S.; Altanlar, N.; Westwell, A.D. Antimicrobial Activities of New Indole Derivatives Containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide. Turkish J. Pharm. Sci. 2018, 15, 291–297. [Google Scholar] [CrossRef]
  26. Mane, Y.D.; Sarnikar, Y.P.; Surwase, S.M.; Biradar, D.O.; Gorepatil, P.B.; Shinde, V.S.; Khade, B.C. Design, synthesis, and antimicrobial activity of novel 5-substituted indole-2-carboxamide derivatives. Res. Chem. Intermed. 2017, 43, 1253–1275. [Google Scholar] [CrossRef]
  27. Schulze, B.; Schubert, U.S. Beyond click chemistry-supramolecular interactions of 1,2,3-triazoles. Chem. Soc. Rev. 2014, 43, 2522–2571. [Google Scholar] [CrossRef]
  28. Küçükgüzel, G.; Çikla-Süzgün, P. Recent advances bioactive 1,2,4-triazole-3-thiones. Eur. J. Med. Chem. 2015, 97, 830–870. [Google Scholar] [CrossRef]
  29. Dilmaghani, K.A.; Nasuhi Pur, F.; Nezhad, M.H. Synthesis and antibacterial evaluation of new thione substituted 1,2,4-triazole schiff bases as novel antimicrobial agents. Iran. J. Pharm. Res. 2015, 14, 693–699. [Google Scholar] [CrossRef]
  30. Metwally, M.A.; Bondock, S.; El-Azap, H.; Kandeel, E.E.M. Thiosemicarbazides: Synthesis and reactions. J. Sulfur Chem. 2011, 32, 489–519. [Google Scholar] [CrossRef]
  31. Palaska, E.; Şahin, G.; Kelicen, P.; Durlu, N.T.; Altinok, G. Synthesis and anti-inflammatory activity of 1-acylthiosemicarbazides, 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazole-3-thiones. Farmaco 2002, 57, 101–107. [Google Scholar] [CrossRef]
  32. Biagi, G.L.; Guerra, M.C.; Barbaro, A.M.; Gamba, M.F. Influence of lipophilic character on the antibacterial activity of cephalosporins and penicillins. J. Med. Chem. 1970, 13, 511–516. [Google Scholar] [CrossRef] [PubMed]
  33. Asami, T.; Mizutani, M.; Shimada, Y.; Goda, H.; Kitahata, N.; Sekimata, K.; Han, S.Y.; Fujioka, S.; Takatsuto, S.; Sakata, K.; et al. Triadimefon, a fungicidal triazole-type P450 inhibitor, induces brassinosteroid deficiency-like phenotypes in plants and binds to DWF4 protein in the brassinosteroid biosynthesis pathway. Biochem. J. 2003, 369, 71–76. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Sarhan, A.E.W.A.O. On the synthesis and reactions of indole-2-carboxylic acid hydrazide. Monatshefte fur Chemie 2001, 132, 753–763. [Google Scholar] [CrossRef]
  35. Coowar, D.; Bouissac, J.; Hanbali, M.; Paschaki, M.; Mohier, E.; Luu, B. Effects of indole fatty alcohols on the differentiation of neural stem cell derived neurospheres. J. Med. Chem. 2004, 47, 6270–6282. [Google Scholar] [CrossRef] [PubMed]
  36. Al-Wabli, R.; Zakaria, A.; Attia, M. Synthesis, Spectroscopic Characterization and Antimicrobial Potential of Certain New Isatin-Indole Molecular Hybrids. Molecules 2017, 22, 1958. [Google Scholar] [CrossRef] [Green Version]
  37. Boraei, A.T.A.; El Ashry, E.S.H.; Duerkop, A. Regioselectivity of the alkylation of S-substituted 1,2,4-triazoles with dihaloalkanes. Chem. Cent. J. 2016, 10, 22. [Google Scholar] [CrossRef] [Green Version]
  38. Vanden Berghe, D.A. Screening methods for antibacterial and antiviral agents from higher plants. Methods Plant. Biochem. 1991, 47–69. [Google Scholar]
  39. Cos, P.; Vlietinck, A.J.; Berghe, D.V.; Maes, L. Anti-infective potential of natural products: How to develop a stronger in vitro “proof-of-concept”. J. Ethnopharmacol. 2006, 106, 290–302. [Google Scholar] [CrossRef]
Molecules 26 02292 sch001 550
Scheme 1. Synthesis of the target compounds 6a-u.
Scheme 1. Synthesis of the target compounds 6a-u.
Molecules 26 02292 sch001
Table
Table 1. Antibacterial activity of the target compounds 6a-u against E. coli, Pseudomonas aeruginosa, Salmonella typhimurium, Staphylococcus aureus, and Bacillus subtilis.
Table 1. Antibacterial activity of the target compounds 6a-u against E. coli, Pseudomonas aeruginosa, Salmonella typhimurium, Staphylococcus aureus, and Bacillus subtilis.
E. coliPseudomonas aeruginosaSalmonella typhimuriumStaphylococcus aureusBacillus subtilis
Compound No.DIZ ± SD *MIC (µg/mL)DIZ ± SD *MIC (µg/mL)DIZ ± SD *MIC (µg/mL)DIZ ± SD *MIC (µg/mL)DIZ ± SD *MIC (µg/mL)
6a11 ± 1.0610000-10 ± 0.0010000-10 ± 0.701000
6b11 ± 0.7025013 ± 7.5025010 ± 0.702500-10 ± 2.12250
6c11 ± 2.1225014 ± 8.0825011 ± 2.882500-9 ± 0.00250
6d10 ± 1.4125015 ± 8.6625011 ± 3.462500-9 ± 0.00250
6e12 ± 1.412500-11 ± 1.732500-9 ± 0.00500
6f11 ± 0.705000-10 ± 0.005000-10 ± 0.70250
6g11 ± 0.7025010 ±5.5025010 ± 1.152500-10 ± 0.70250
6h12 ± 1.4125010 ± 1.0025010 ± 0.575009 ± 0.5710000-
6i12 ± 2.1225011 ± 1.5225010 ± 0.702509 ± 1.522500-
6j14 ± 3.53100012 ± 1.3250011 ± 0.3550011 ± 1.415000-
6k14 ± 3.5325011 ± 0.5725010 ± 0.5725010 ± 1.412500-
6l14 ± 3.5325010 ± 1.152509 ± 0.0025011 ± 1.005000-
6m12 ± 2.8225010 ± 0.5725010 ± 1.7325010 ± 0.572500-
6n13 ± 2.1250012 ± 1.1525011 ± 1.0025011 ± 1.002500-
6o11 ± 0.70100013 ± 2.51100011 ± 1.0010000-0-
6p11 ± 0.0050012 ± 2.0050011 ± 2.005000-0-
6q12 ± 1.0650012 ± 1.5225011 ± 1.152500-0-
6r12 ± 0.7025013 ± 2.6450012 ± 1.522500-0-
6s10 ± 1.4125014 ± 3.6025011 ± 1.525000-0-
6t11 ± 0.0050013 ± 3.0150011 ± 1.735000-0-
6u11 ± 1.41100013 ± 2.00100012 ± 1.1510000-12 ± 1.00250
Ampicillin08 ± 0.5750024 ± 0.40100014 ± 0.60500050008 ± 0.28500
* The arithmetic mean of the inhibition zone diameters in mean ± standard deviation. (-) not determined.
Table
Table 2. Antifungal activity of the target compounds 6a-u against Candida albicans, Candida tropicalis, and Candida glabrata.
Table 2. Antifungal activity of the target compounds 6a-u against Candida albicans, Candida tropicalis, and Candida glabrata.
Candida albicansCandida tropicalisCandida glabrata
Compound No.DIZ ± SD *MIC (µg/mL)DIZ ± SD *MIC (µg/mL)DIZ ± SD *MIC (µg/mL)
6a26 ± 0.28100013 ± 0.57210 ± 0.571000
6b26 ± 0.1125014 ± 1.52210 ± 0.00250
6c26 ± 0.2825014 ± 2.08210 ± 0.57250
6d27 ± 0.0025014 ± 3.46410 ± 1.00125
6e26 ± 0.2825014 ± 3.21411 ± 1.15250
6f26 ± 0.28214 ± 2.00410 ± 0.00250
6g26 ± 0.1125014 ± 1.15410 ± 0.571000
6h0-12 ± 0.5720
6i0-11 ± 0.5740-
6j0-11 ± 0.5740-
6k0-10 ± 0.0020-
6l0-10 ± 0.0020-
6m0-10 ± 0.5720-
6n0-11 ± 0.5720-
6o11 ± 0.70100011 ± 0.57160-
6p10 ± 0.003211 ± 0.5740-
6q10 ± 0.703211 ± 0.5712.50-
6r10 ± 0.703214 ± 0.5720-
6s10 ± 0.0025012 ± 1.52210 ± 0.5762.5
6t11 ± 0.7025011 ± 0.57210 ± 0.5732
6u10 ± 0.00100017 ± 0.28213 ± 1.0016
Fluconazole07 ± 0.2825015 ± 0.11 100015 ± 0.571000
* The arithmetic mean of the inhibition zone diameters in mean ± standard deviation. (-) not determined.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Al-Wabli, R.I.; Alsulami, M.A.; Bukhari, S.I.; Moubayed, N.M.S.; Al-Mutairi, M.S.; Attia, M.I. Design, Synthesis, and Antimicrobial Activity of Certain New Indole-1,2,4 Triazole Conjugates. Molecules 2021, 26, 2292. https://doi.org/10.3390/molecules26082292

AMA Style

Al-Wabli RI, Alsulami MA, Bukhari SI, Moubayed NMS, Al-Mutairi MS, Attia MI. Design, Synthesis, and Antimicrobial Activity of Certain New Indole-1,2,4 Triazole Conjugates. Molecules. 2021; 26(8):2292. https://doi.org/10.3390/molecules26082292

Chicago/Turabian Style

Al-Wabli, Reem I., Mona A. Alsulami, Sarah I. Bukhari, Nadine M. S. Moubayed, Maha S. Al-Mutairi, and Mohamed I. Attia. 2021. "Design, Synthesis, and Antimicrobial Activity of Certain New Indole-1,2,4 Triazole Conjugates" Molecules 26, no. 8: 2292. https://doi.org/10.3390/molecules26082292

Article Metrics

Back to TopTop